{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"}],"units":"Participants"}],"description":"The PPQ is an instrument that has been developed from participant interviews and includes questions to evaluate directly from participants their preference regarding mode of administration, as well as the strength of the preference, and the reason for the preference. The PPQ does not have any pre-defined scale or associated numerical scoring and answer choices are qualitative. Question 1 in the PPQ evaluates participants' preferred method of administration with response options of IV, SC or \"no preference\". As pre-specified by the protocol, the percentage of participants who preferred SC administration (participant preference rate \\[PPR\\]) was reported out of all randomized participants who received all 3 doses of Pembrolizumab IV and Pembrolizumab SC during treatment crossover period and answered at least question 1 of the PPQ on Cycle 6 Day 1 (Day 106).","groups":[{"description":"Randomized participants received three doses of pembrolizumab plus berahyaluronidase alfa SC and three doses of pembrolizumab IV during the Treatment Crossover Period and subsequently answered question 1 of the PPQ on Day 106.","id":"OG000","title":"Full Analysis Set"}],"paramType":"NUMBER","populationDescription":"Per protocol, the analysis population (Full Analysis Set) included all randomized participants who received all three doses of pembrolizumab plus berahyaluronidase alfa SC and all three doses of pembrolizumab IV during the Treatment Crossover Period, and subsequently answered question 1 of the PPQ on Day 106.","reportingStatus":"POSTED","timeFrame":"Day 106","title":"Percentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 1","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}